



March 16, 2020

**Re: Intervention™ efficacy against SARS-CoV-2, the virus which causes COVID-19 disease**

Dear Sir or Madam,

In cases of emerging viral pathogens like SARS-CoV-2, the virus that causes COVID-19, when there is no test that can be conducted to validate the efficacy of a disinfectant, the EPA utilizes Emerging Viral Pathogen Guidance to determine the expected efficacy of a disinfectant against an emerging virus. This guidance, used previously during the 2003 SARS epidemic, mandates that for disinfectant products to be approved, they must be an EPA registered Hospital or Broad-Spectrum disinfectant and have proven efficacy against two small, non-enveloped viruses, such as Poliovirus and Parvovirus. The following criteria are used to determine efficacy of a disinfectant upon activation of the Emerging Pathogen Rule:

1. The product must be a hospital or broad-spectrum disinfectant product registered with EPA.
2. For an emerging enveloped virus, the product must have acceptable efficacy data previously submitted to and reviewed by the Agency against one non-enveloped virus (e.g. Poliovirus).

The Intervention™ line of disinfectants (concentrate and premoistened wipes) fulfill these criteria and are included on the EPA's List N: Disinfectants for Use Against SARS-CoV-2. Simply search by the EPA Registration Number; 74559-4 for the concentrate and 74559-10 for the premoistened wipes. (<https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2>).

The Intervention™ line of disinfectants can be used against SARS-CoV-2 as part of a facility's COVID-19 infection prevention and control plan on hard, non-porous surfaces. Intervention™ concentrate should be applied at a 1:64 dilution for a contact time of five minutes. Intervention™ wipes should be applied with a one-minute contact time. Refer to the CDC website at [www.cdc.gov/outbreaks/](http://www.cdc.gov/outbreaks/) for additional information.

Should you require any further information, please do not hesitate to contact me directly at 1-800-387-7578 ext. 118 or via email at [nkenny@virox.com](mailto:nkenny@virox.com).

Best Regards,

Nicole Kenny, HBSc., Assoc Chem  
Vice President, Professional and Technical Services  
Virox Technologies Inc.



LEED®  
Silver  
Certified

